BioCryst Pharmaceuticals

ISIN US09058V1035

 | 

WKN 896047

Market cap (in EUR)
1,334 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 1,334 m
EPS, EUR -0.04
P/B ratio -
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 417 m
Net income, EUR -82 m
Profit margin -19.72%

What ETF is BioCryst Pharmaceuticals in?

There are 4 ETFs which contain BioCryst Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of BioCryst Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.13%
Equity
United States
Health Care
Biotech
44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
491
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.02%
Equity
United States
Small Cap
180
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.